Two thirds of people diagnosed with Alzheimer’s are women. Research shows that the Alzheimer’s biomarker tau protein accumulates differently and more quickly in women’s…
As the vast majority of Alzheimer’s drugs fail in clinical trials, some researchers and companies are turning to non-invasive neurotechnology as an alternative approach…
Two thirds of people diagnosed with Alzheimer’s are women. In addition, research shows that Alzheimer’s biomarker tau protein accumulates differently and more quickly in…
Diagnosed with Alzheimer’s and one of the relative few who has gotten a prescription for the new, disease-modifying anti-amyloid drug Leqembi? If you live…
There are different modalities of drugs, delivered in different formats, that work in different ways. One type of drug you may encounter often is…
Open your medicine cabinet, and you’ll see many examples of the most common type of medication on the market: Small molecule drugs such as…
An article published this week in the prestigious journal Nature Medicine documents what is believed to be the first evidence that Alzheimer’s disease can…
The most common form of dementia, Alzheimer’s, is a progressive, life limiting, neurodegenerative condition, which damages and destroys parts of the nervous system, especially…
From the crispy crunch of fresh veggies to the creamy indulgence of decadent desserts, we all have different food preferences. Our palates develop uniquely,…
Scientists are looking for ways to detect cognitive decline and Alzheimer’s faster, so that they could treat the disease sooner. The holy grail of…
Dementia is a term used to describe a set of symptoms: memory loss and other cognitive issues. The most common disease that causes these…
People living with Alzheimer’s disease also live with a higher risk of seizures. And that can make things complicated for doctors: Seizures are sometimes…
In the last three years, amyloid plaque-busting drugs Aduhelm (now discontinued) and Leqembi have been approved by the FDA for treating patients in the…
Scientists have developed more tools than ever to probe Alzheimer’s — from blood tests, to AI-powered cognitive assessments, and brain scans — which have…
The monoclonal antibody drugs targeting the brain’s amyloid plaques dominated the news cycle in 2023. Eisai and Biogen’s Leqembi was approved by the FDA…